This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
10 - 12 June, 2025
Congress CenterBasel Switzerland

Dr. Christoph Schatz, PhD
Senior Science Fellow / Targeted Alpha Therapy VI at Bayer AG


Christoph did his master thesis research at Harvard Medical School in Boston. He received his PhD from EMBL in Heidelberg, Germany. In 2003 Christoph joined the Biotech Epiontis working on biomarkers for immunotherapy and moved on to the oncology group at Bayer in 2006. He has profound knowledge in drug development and translational science. In the last seven years Christoph was leading preclinical research teams driving the development of radiolabeled conjugates for the treatment of cancer from the preclinical stage into early clinical development. Christoph is currently a Senior Scientist at the Bayer Research site in Berlin, Germany.

Agenda Sessions

  • Preclinical Efficacy of a PSMA-targeted Actinium-225 conjugate (225Ac- pelgifatamab/ BAY 3546828) - A Targeted Alpha Therapy for Prostate Cancer